宫颈癌患者五年生存及影响因素分析

doi:10.11904/j.issn.1002-3070.2022.01.002

实用肿瘤学杂志 ›› 2022, Vol. 36 ›› Issue (1): 7-13.doi: 10.11904/j.issn.1002-3070.2022.01.002

宫颈癌患者五年生存及影响因素分析

张艺艺¹, 李奇², 刘旭¹, 王亚楠¹, 邹沅杰¹, 周慧慧^1,3, 徐春燕^1,4, 苏升琦¹, 葛鑫², 王铜¹

1.哈尔滨医科大学地方病控制中心克山病研究所(哈尔滨 150081);
2.哈尔滨医科大学附属肿瘤医院;
3.济宁医学院;
4.塔里木大学

收稿日期:2021-03-27 修回日期:2021-11-05 出版日期:2022-02-28 发布日期:2022-01-21
通讯作者: 李奇,E-mail:liqi@ems.hrbmu.edu.cn
作者简介:张艺艺,女,(1995-),硕士研究生,从事宫颈癌疗效的观察实效学研究。
基金资助:
黑龙江省博士后科研启动金(编号:LBH-Q17096);哈医大肿瘤医院海燕基金重点项目(编号:JJZD2021-16)

Analysis of 5-year survival and its influencing factors of patients with cervical cancer

ZHANG Yiyi¹, LI Qi², LIU Xu¹, WANG Yanan¹, ZOU Yuanjie¹, ZHOU Huihui^1,3, XU Chunyan^1,4, SU Shengqi¹, GE Xin², WANG Tong¹

1. Institute of Keshan Disease,Chinese Center for Endemic Disease Control,Harbin Medical University,Harbin 150081,China;
2. Harbin Medical University Cancer Hospital;
3. Jining Medical University;
4. Tarim University

Received:2021-03-27 Revised:2021-11-05 Online:2022-02-28 Published:2022-01-21

摘要/Abstract

摘要： 目的观察宫颈癌患者生存与病情进展状态,并探究其影响因素,为改善预后提供依据。方法本研究纳入2013年1月—2015年12月于哈尔滨医科大学附属肿瘤医院就诊的2 306例宫颈癌患者,对其进行回顾和随访,采用Kaplan-Meier法分析宫颈癌患者总生存期(OS)和无进展生存期(PFS),用Cox风险比例回归模型分析生存期影响因素。结果 Ⅰ、Ⅱ、Ⅲ、Ⅳ期患者5年生存率分别为87.3%、79.3%、61.8%、36.8%;5年无进展生存率为82.9%、73.0%、55.6%和0。中位随访时间为51.0个月,单因素分析显示发病年龄、绝经情况、产次数、孕次数、心脏病史、流产史、淋巴结状态、脉管癌栓、FIGO分期、精神、饮食状态和末产年龄与患者OS和PFS有关。多因素分析显示末产年龄、淋巴结状态、脉管癌栓和间质层浸润程度是影响OS和PFS的独立因素。结论除病理特征外,多孕、多产和末产年龄大也是宫颈癌患者预后不良的危险因素。

关键词: 宫颈癌, 随访, 总生存期, 无进展生存期, 疗效比较学研究

Abstract: Objective This study aimed to observe the survival and progress of patients with cervical cancer,and to explore its influencing factors,so as to provide evidence for improving the prognosis.Methods A total of 2 306 cervical cancer patients hospitalized in Harbin Medical University Cancer Hospital between January 2013 and December 2015 were included for reviewed and followed up.The Kaplan-Meier method was used to analyze the overall survival and progression-free survival of cervical cancer patients.The Cox risk proportional regression model was used to analyze the influencing factors of survival.Results The 5-year survival rates of stage Ⅰ,Ⅱ,Ⅲ and Ⅳ patients were 87.3%,79.3%,61.8%,and 36.8%,respectively;the 5-year progression-free survival rates were 82.9%,73.0%,55.6%,and 0,respectively.The median follow-up time was 51.0 months.Univariate analysis showed that the age of diagnosis,menopausal status,the number of births,history of heart disease,the history of abortion,lymph node status,vascular cancer thrombus,FIGO staging,mentality,diet status,and age of final delivery,etc.were related to the patient's OS and PFS.Multivariate analyses showed that age at final delivery,lymph node status,vascular tumor thrombus and the degree of interstitial invasion were independent factors that affected the OS and PFS.Conclusion In addition to pathological features,multiple pregnancy,multiple births,and older age at final delivery are risks factors for poor prognosis of the patients with cervical cancer.

Key words: Cervical cancer, Follow-up, Overall survival, Progression-free survival, Comparative study of efficacy

中图分类号:

R737.33

张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.

ZHANG Yiyi, LI Qi, LIU Xu, WANG Yanan, ZOU Yuanjie, ZHOU Huihui, XU Chunyan, SU Shengqi, GE Xin, WANG Tong. Analysis of 5-year survival and its influencing factors of patients with cervical cancer[J]. Journal of Practical Oncology, 2022, 36(1): 7-13.

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
3 Wu C,Li M,Meng H,et al.Analysis of status and countermeasures of cancer incidence and mortality in China[J].Sci China Life Sci,2019,62(5):640-647.
4 World Health Organization Latest global cancer data:Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020.(2020-12-15)[2021-11-15]https://www.iarc.who.int/faq/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/.
5 陈万青,孙可欣,郑荣寿,等.2014年中国分地区恶性肿瘤发病和死亡分析[J].中国肿瘤,2019,27(1):1-14.
6 Djulbegovic B,Guyatt GH.Progress in evidence-based medicine:a quarter century on[J].Lancet,2017,390(10092):415-423.
7 Choi J.Comparative effectiveness research in observational studies[J].J Periodontal Implant Sci,2018,48(6):335-336.
8 徐梅梁,宋涛.晚期宫颈癌放化疗患者生活质量影响因素分析[J].中国妇幼保健,2021,36(3):641-644.
9 任思颖,秦明芳,陈杨,等.云南省肿瘤登记地区2011—2015年宫颈癌发病和死亡特征及时间趋势[J].实用肿瘤学杂志,2021,35(1):13-17.
10 谢珊艳,任鹏.宫颈癌发病年轻化的趋势分析与相应对策[J].中医药管理杂志,2018,26(5):10-12.
11 Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14(CONCORD-3):analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023-1075.
12 Hu K,Wang W,Liu X,et al.Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy[J].Radiat Oncol,2018,13(1):249.
13 Grjibovski AM,Dubovichenko D,Saduakassova S,et al.Incidence,mortality and determinants of survival from cervical cancer in Northwest Russia:a registry-based cohort study[J].Int Health,2018,10(2):92-99.
14 Moon EK,Oh CM,Won YJ,et al.Trends and age-period-cohort effects on the incidence and mortality rate of cervical cancer in korea[J].Cancer Res Treat,2016,49(2):526-533.
15 潘敏.560例绝经后妇女的宫颈病变特点分析[J].实用中西医结合临床,2006,6(5):54-55.
16 张蕾,忙尼沙·阿不都拉,胡尔西旦·尼牙孜,等.早期宫颈癌患者预后影响因素研究[J].中国全科医学,2011,14(14):1517-1522.
17 Beharee N,Shi Z,Wu D,et al.Diagnosis and treatment of cervical cancer in pregnant women[J].Cancer Med,2019,8(12):5425-5430.
18 Escande A,Gouy S,Mazeron R,et al.Outcome of early stage cervical cancer patients treated according to a radiosurgical approach:Clinical results and prognostic factors[J].Gynecol Oncol,2017,144(3):541-546.
19 Kwon J,Eom KY,Kim YS,et al.The prognostic impact of the number of metastatic lymph nodes and a new prognostic scoring system for recurrence in early-stage cervical cancer with high risk factors:A multicenter cohort study(KROG 15-04)[J].Cancer Res Treat,2018,50(3):964-974.
20 Bhatla N,Denny L.FIGO cancer report 2018[J].Int J Gynaecol Obstet,2018,143(2):2-3.

[1]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[2]	姚丽萍, 王宏宗, 丁高恒, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区宫颈癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 224-230.
[3]	胡海, 黎杰, 王培, 唐斌, 王先良, 杨强. 宫颈癌后装治疗中基于U-net的自动施源器分割[J]. 实用肿瘤学杂志, 2021, 35(3): 248-253.
[4]	秦伟, 何义富, 常娜, 钱立庭, 黄大兵, 崔亚云. 局部晚期宫颈癌放射治疗对直肠功能影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 170-173.
[5]	任思颖,秦明芳,陈杨,石青萍,成会荣,高娇,文洪梅. 云南省肿瘤登记地区2011—2015年宫颈癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(1): 13-17.
[6]	李建昕, 沈彬杰, 王璇. 恶性肿瘤社区随访模式的研究进展[J]. 实用肿瘤学杂志, 2020, 34(6): 540-543.
[7]	李静, 王玉霞, 陈杰. 长链非编码RNA HOTAIR在宫颈癌中的相关研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 368-371.
[8]	罗丽芳, 刘运铎, 关玥, 陈秀玮. 基于槲皮素标记的金属有机框架放疗联合阿霉素诱导宫颈癌HeLa细胞凋亡的研究[J]. 实用肿瘤学杂志, 2020, 34(3): 203-207.
[9]	秦凯, 程熠, 袁响林, 简丹妮, 张菁, 黄乐. 超声膀胱容量监测技术在宫颈癌术后调强放疗中的应用价值[J]. 实用肿瘤学杂志, 2020, 34(3): 232-236.
[10]	杨东明, 卢庆刚. “半野”三维适形放疗、固定野静态调强放疗和容积旋转调强放疗在中晚期宫颈癌治疗上的剂量学比较[J]. 实用肿瘤学杂志, 2020, 34(3): 244-248.
[11]	曹宁, 夏百荣, 娄阁. HPV蛋白、miRNAs和外泌体在宫颈癌炎症作用中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 282-285.
[12]	周瑶瑶, 陈凤云, 屠文骆. 棕榈酸在体外通过促进凋亡作用抑制宫颈癌Hela细胞增殖的研究[J]. 实用肿瘤学杂志, 2019, 33(5): 402-406.
[13]	申利, 魏军成. miRNA-409-3p表达水平对宫颈癌细胞增殖及顺铂化疗敏感性的影响[J]. 实用肿瘤学杂志, 2019, 33(4): 300-304.
[14]	李景, 吴华珍, 刘继琐. miR-362靶向Six1抑制宫颈癌细胞增殖、迁移的作用机制研究[J]. 实用肿瘤学杂志, 2019, 33(4): 310-316.
[15]	梁虹, 李奇, 王耀先, 靳红, 王铜, 王亚楠, 段雅妮, 宋敏. 宫颈癌化疗心血管毒性预防的间断时间序列试验[J]. 实用肿瘤学杂志, 2019, 33(2): 134-138.

宫颈癌患者五年生存及影响因素分析

Analysis of 5-year survival and its influencing factors of patients with cervical cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价